PTPRC and Miyoshi myopathy: The most aggressive MM subclones, which will be selected during the evolution of MM, will be characterized by a strong capacity to destroy bone trabeculae and by their potential to grow thank to the best kinome-phosphatasome profile that is the lack of CD45 parallel to the aberrant expression of CD221/IGF1R (71).